Purchase this article with an account.
A. Barrera, V. Cubas-Lorenzo, A. Solis-Vivanco, H. Quiroz-Mercado, J. Fromow-Guerra, J. Guerrero-Naranjo; Contamination of Bevacizumab (Avastin) Glass Vials. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1749.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the possible contamination of bevacizumab (Avastin) glass vials in an in-office storage and utilization procedure for syringe preparation for intravitreal treatments
We evaluated 11 bevacizumab (Avastin) glass vials used in different times during 1 year of practice. All vials were storage at 4°C and used during one month for intravitreal treatments for various pathologies. Before the aspiration of the bevacizumab for the preparation of the syringe, the top of the vial was cleaned with povidone 10%. After one month of use the vial was storaged at 4°C and not used again. The asses of contamination was done by cultivation using Brain hearth infusion, Blood agar , Chocolate Agar , Stafilococus 110 Agar , Eosine Methilene Blue Agar , Mac’Conkey Agar, during 3 day of cultivation.
During 3 day of cultivation none growth was determinate.
Our results suggest that this office procedure of storage and preparation of bevacizumab syringe doses maintains Avastin glass vials free ofcontamination and can be used safetly for long periods of time.
This PDF is available to Subscribers Only